A. Tong

发表

Small RNAs and non-small cell lung cancer.

A. Tong, 2006, Current molecular medicine.

Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

N. Senzer, J. Nemunaitis, A. Tong, 2011, Clinical Cancer Research.

Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

J. Nemunaitis, A. Tong, J Nemunaitis, 2008, Cancer Gene Therapy.

miRNA profiling for diagnosis and prognosis of human cancer.

Chris Jay, Pat Fulgham, J. Nemunaitis, 2007, DNA and cell biology.

Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells

A. Tong, E. Gomes, Margret S. Rodrigues, 2009, Clinical Cancer Research.

Prospects for CD40-directed experimental therapy of human cancer

A. Tong, M. Stone, 2003, Cancer Gene Therapy.

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)

N. Senzer, J. Nemunaitis, A. Tong, 2008, Gene regulation and systems biology.

Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma.

G. Klintmalm, D. Su, A. Tong, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biomarkers Analysis for Heterogeneous Immune Responsesof Quiescent CD8+cells -A Clue for Personalized Immunotherapy

Jie Zheng, Biaoru Li, A. Tong, 2015 .

Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD40 Ligand Transgene

A. Tong, E. Gomes, Lindsay D. Butcher, 2009, Clinical Cancer Research.

Endogenous Expression in Human Breast Cancer Growth-inhibitory Effects of CD 40 Ligand ( CD 154 ) and Its Updated Version

G. Netto, A. Tong, M. Stone, 2001 .

Growth-inhibitory Effects of CD 40 Ligand ( CD 154 ) and Its Endogenous Expression in Human Breast Cancer 1

G. Netto, A. Tong, M. Stone, 2001 .

Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.

G. Netto, A. Tong, G. Netto, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

AntitumorActivity of an Oncolytic Adenoviral-CD 40 Ligand ( CD 154 ) Transgene Construct in Human Breast Cancer Cells

A. Tong, E. Gomes, Margret S. Rodrigues, 2009 .

Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.

Yuan Zhang, N. Senzer, J. Nemunaitis, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Monoclonal Antibodies: A New Horizon for Cancer Treatment

A. Tong, M. Stone, 1988 .

Quantification of Non-Light Chain Amyloid Precursors and Acute Phase-Related Proteins in AL-Amyloid Sera.

A. Tong, M. Stone, Amanda Burfoot, 1991 .

Elimination of chemoresistant multiple myeloma clonogenic colony-forming cells by combined treatment with a plasma cell-reactive monoclonal antibody and a P-glycoprotein-reactive monoclonal antibody.

J. Fay, T. Tsuruo, W. Dalton, 1989, Cancer research.

Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.

A. Tong, M. Stone, J. Lee, 1989, Cancer research.

Oncolytic viruses for induction of anti-tumor immunity.

N. Senzer, J. Nemunaitis, A. Hemminki, 2012, Current pharmaceutical biotechnology.

Cancer Therapy : Preclinical Growth Inhibition of Human Multiple Myeloma Cells by an Oncolytic Adenovirus Carrying the CD 40 Ligand Transgene

A. Tong, E. Gomes, Lindsay D. Butcher, 2009 .

Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease.

Y. W. Huang, E. Vitetta, A. Tong, 1993, Cancer research.

Elevated serum erythropoietin in a patient with polycythaemia vera presenting with Budd-Chiari syndrome

A. Tong, Catherine M Jones, Yair Levy, 2014, BMJ Case Reports.

Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice.

Y. W. Huang, G. Netto, E. Vitetta, 1993, Anticancer research.

Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2

N. Senzer, J. Nemunaitis, N. Templeton, 2009, Gene regulation and systems biology.

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

N. Senzer, J. Nemunaitis, T. Fujiwara, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

N. Senzer, J. Nemunaitis, B. Sands, 2007, Cancer Gene Therapy.

Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph+ pre-B acute lymphoblastic leukaemia

A. Tong, Yair Levy, C. Maisel, 2014, BMJ Case Reports.

Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complement.

J. Fay, A. Tong, M. Stone, 1987, Blood.

Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.

Yuan Zhang, R. Ramesh, N. Senzer, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression

R. Glazer, Hongyan Yuan, Lu Jin, 2022, Oncotarget.

K- ras Ribozyme for Lung Cancer

J. Nemunaitis, A. Tong, G. Mues, 1998 .

Cellular Immune Profile of Patients With Advanced Cancer Before and After Taxane Treatment

A. Tong, P. Maples, D. Richards, 2000, American journal of clinical oncology.

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

J. Nemunaitis, G. Netto, D. Kirn, 2001, Gene Therapy.

Human monoclonal macroglobulins with antibody activity.

A. Pestronk, A. Tong, J. Newman, 2003, Seminars in oncology.

Generation of ribozyme-adenoviral vector against K-ras mutant human lung cancer cells

J. Nemunaitis, A. Tong, Yu-An Zhang, 2000, Molecular biotechnology.

Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.

J. Nemunaitis, A. Tong, Patrick Chen, 2006, Cancer research.

MicroRNA profile analysis of human prostate cancers

A. Eklund, I. Khalil, N. Senzer, 2009, Cancer Gene Therapy.

Oncolytic viral therapy for human cancer: Challenges revisited

A. Tong, 2005 .

Prognostic Role of K-ras in Patients with Progressive Colon Cancer Who Received Treatment with Marimastat (BB2516)

J. Nemunaitis, A. Tong, J. Cox, 2000, Cancer investigation.

Small interfering RNA for experimental cancer therapy.

J. Nemunaitis, A. Tong, Yu-an Zhang, 2005, Current opinion in molecular therapeutics.

CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity.

A. Tong, M. Stone, 1996, Leukemia & lymphoma.

Proof concept for clinical justification of network mapping for personalized cancer therapeutics

I. Khalil, C. Hill, D. Rao, 2007, Cancer Gene Therapy.

Phenotypic and genotypic alterations characterize patients bearing plasma cell dyscrasias with a high M‐component

A. Mosiello, A. Cianciulli, A. Tong, 1999, Cell proliferation.

Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients

J. Nemunaitis, G. Netto, L. Post, 2003, Cancer Gene Therapy.

Phase II Study of LucanixTM (Belagenpumatucel) a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)

J. Nemunaitis, P. Schwarzenberger, R. Dillman, 2016 .

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.

N. Senzer, J. Nemunaitis, P. Schwarzenberger, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD40 Ligand-Induced Apoptosis is Fas-Independent in Human Multiple Myeloma Cells

A. Tong, Dan Su, M. Stone, 2000, Leukemia & lymphoma.

Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.

A. Tong, M. Stone, J. Lee, 1984, Cancer research.

Lobular Carcinoma of the Breast with Gastrointestinal Metastasis

A. Tong, Catherine M Jones, M. Mir, 2015, Proceedings.

Flow cytofluorometric detection of tumor-specific rosette-forming cells in patients with squamous cell carcinoma of the head and neck.

W. Kraybill, A. Tong, R. Vetto, 1982, Cancer research.

Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer.

A. Tong, D. Shawler, H. Fakhrai, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

N. Senzer, J. Nemunaitis, W. Gahl, 2011, Human gene therapy.

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy

N. Senzer, J. Nemunaitis, W. Gahl, 2010, The journal of gene medicine.

Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression.

A. Tong, G. Babbage, Padmasini Kumar, 2005, Clinical lymphoma.

In vivo safety and antitumor efficacy of bifunctional small hairpin RNAs specific for the human Stathmin 1 oncoprotein.

H. Frieboes, D. Rao, N. Senzer, 2011, DNA and cell biology.

Anti-CD40 antibody binding modulates human multiple myeloma clonogenicity in vitro.

A. Tong, G. Mues, M. Stone, 1994, Blood.

Potential clinical application of antioncogene ribozymes for human lung cancer.

J. Nemunaitis, A. Tong, P. Maples, 2001, Clinical lung cancer.

Anti-K-ras1 Ribozyme Adenoviral Vector for Gene Therapy of Non-Small Cell Lung Cancer.

A. Tong, J. Nemunaitis, Y. Zhang, 2000, Methods in molecular medicine.

Serum interleukin-10 levels in patients affected with multiple-myeloma - correlation with the monoclonal component and disease progression.

S. Alvino, A. Tong, F. Pimpinelli, 1995, International journal of oncology.

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

N. Senzer, J. Nemunaitis, T. Fujiwara, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Expression of Plasma Cell-Associated Non-Light Chain Antigens in Patients with Plasma Cell Dyscrasia and Amyloidosis

Jennifer C. Lee, A. Tong, M. Stone, 1988 .

Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodies.

A. Tong, M. Stone, J. Lee, 1986, Journal of the National Cancer Institute.

Systemic therapeutic gene delivery for cancer: crafting Paris' arrow.

N. Senzer, J. Nemunaitis, A. Tong, 2009, Current gene therapy.

Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.

A. Tong, G. Mues, M. Stone, 1998, American journal of clinical oncology.

1104. Phase II Study of Lucanix™ a Transforming Growth Factor β2 (TGF-β2) Antisense Gene Modified Allogeneic Tumor Cell Vaccine in Non Small Cell Lung Cancer (NSCLC)

N. Senzer, J. Nemunaitis, P. Schwarzenberger, 2006 .